TABLE 4.
Binding and neutralization of AAV-2 capsid mutants by IVIG
| Mutationa | Fold decrease in binding | Fold increase in resistance to neutralizationb |
|---|---|---|
| None (wild type) | 1 | 1 |
| S264A | NT | 2* |
| G265A | NT | 4* |
| S267A | 1 | 1 |
| S267T | 1 | 1 |
| D269N | 1 | 4* |
| N270A | NT | 1 |
| H271Q | 1 | 1 |
| G383A | 1 | NT |
| R471A | 1 | 2* |
| T491A | NT | 2* |
| D494E | 1 | 2 |
| D494N | NT | 2 |
| N497H | 1 | NT |
| N497H/S498A | NT | 2* |
| W502A | NT | 10* |
| H509K | 1 | 1 |
| H509Q | 1 | NT |
| G512P | NT | 2 |
| D514A | NT | 2 |
| K527A | NT | 2* |
| E530D | 1 | NT |
| E531A | NT | 1 |
| E531K | NT | 2* |
| K532A | NT | 5* |
| F533A | NT | 2 |
| K544A | NT | 3* |
| T550K | 1 | 3* |
| E555A | NT | 1 |
| E574A | NT | 2* |
| Q575A | NT | 1 |
| R585K | NT | 1 |
| G586A | 1 | 3* |
| N587A | NT | 1 |
| Q589A | NT | 1 |
| N705A | 1 | 2* |
| N705K | 1 | NT |
| K706A | NT | 4* |
| V708A | 1 | 4* |
| V708K | 10* | 1 |
| R471A/G586A | 1 | 4* |
| R471A/N705A | 1 | 2* |
| E548A/T550A | 1 | NT |
| G586A/N705A | 1 | 2 |
| N705A/V708A | 1 | 2* |
| R471A/G586A/N705A | 1 | 3* |
| E548A/T550A/G586A/N587A | 1 | 1 |
| E548A/T550A/G586A/N587A/ N705A/V708A | NT | 1 |
a
Mutations are as described in Table 1, footnote a.
b
Titers were determined as described in Materials and Methods. Data are presented as ratios of the titer of the serum against virions with mutant capsids to the titer of the serum against virions with wild-type capsids. The neutralization titer of IVIG (10 mg/ml) for rAAV-2 lacZ with a wild-type capsid was 1:312 ± 126. *, statistically different from wild-type results (P < 0.05); NT, not tested.